NASDAQ:XBIT XBiotech (XBIT) Stock Price, News & Analysis $2.19 +0.01 (+0.46%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$2.18 -0.01 (-0.46%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About XBiotech Stock (NASDAQ:XBIT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XBiotech alerts:Sign Up Key Stats Today's Range$2.16▼$2.2250-Day Range$2.15▼$2.4652-Week Range$2.09▼$3.44Volume66,070 shsAverage Volume50,154 shsMarket Capitalization$66.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview XBiotech Inc. is a biotechnology company focused on developing therapies that target inflammation and other disease processes. The company’s technology platform is based on “True Human” monoclonal antibodies, which are derived from naturally occurring human antibodies rather than genetically engineered or animal-derived antibody sequences. XBiotech’s research has included bermekimab, a fully human antibody designed to neutralize interleukin-1 alpha, an inflammatory protein associated with cancer, autoimmune conditions and other diseases. The company has evaluated bermekimab in clinical studies involving cancer and inflammatory disorders, while continuing to research additional antibody-based treatments and potential applications. Founded in 2005 and headquartered in Austin, Texas, XBiotech has pursued the discovery, development and potential commercialization of biological therapies for patients in the United States and international markets. John Simard, the company’s founder, has served as its chairman and chief executive officer.AI Generated. May Contain Errors. Read More XBiotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreXBIT MarketRank™: XBiotech scored higher than 3% of companies evaluated by MarketBeat, and ranked 885th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingXBiotech has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageXBiotech has only been the subject of 1 research reports in the past 90 days.Read more about XBiotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of XBiotech is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XBiotech is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXBiotech has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.62% of the float of XBiotech has been sold short.Short Interest Ratio / Days to CoverXBiotech has a short interest ratio ("days to cover") of 13.17, which indicates bearish sentiment.Change versus previous monthShort interest in XBiotech has recently increased by 2.96%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXBiotech does not currently pay a dividend.Dividend GrowthXBiotech does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for XBiotech this week, compared to 0 articles on an average week. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XBiotech insiders have not sold or bought any company stock.Percentage Held by Insiders30.80% of the stock of XBiotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.70% of the stock of XBiotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about XBiotech's insider trading history. Receive XBIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XBIT Stock News HeadlinesXBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50-Day Moving Average - What's Next?September 15, 2026 | americanbankingnews.comXBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial SpondyloarthritisJune 15, 2026 | globenewswire.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. | The Oxford Club (Ad)XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ RadarMay 14, 2026 | tipranks.comXBiotech: Q4 Earnings SnapshotMarch 13, 2026 | chron.comXBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?October 28, 2025 | msn.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insidersAugust 28, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBITFebruary 4, 2025 | prnewswire.comSee More Headlines XBIT Stock Analysis - Frequently Asked Questions How have XBIT shares performed this year? XBiotech's stock was trading at $2.39 at the beginning of 2026. Since then, XBIT stock has decreased by 8.4% and is now trading at $2.19. How were XBiotech's earnings last quarter? XBiotech Inc. (NASDAQ:XBIT) posted its earnings results on Thursday, August, 13th. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing the consensus estimate of $0.03 by $0.25. When did XBiotech IPO? XBiotech (XBIT) raised $76 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO. Who are XBiotech's major shareholders? XBiotech's top institutional investors include BlackRock Inc. (1.05%), Empowered Funds LLC (0.20%), Bank of New York Mellon Corp (0.13%) and Squarepoint Ops LLC (0.11%). View institutional ownership trends. How do I buy shares of XBiotech? Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XBiotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that XBiotech investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AUO (AUOTY). Company Calendar Last Earnings8/13/2026Today9/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (27m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 XBIT's financial health is in the Red zone, according to TradeSmith. XBIT has been in this zone for over 27 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XBIT CIK1626878 Webwww.xbiotech.com Phone(512) 386-2900Fax512-386-5505Employees87Year Founded2005Profitability EPS (Trailing Twelve Months)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.54 million Net MarginsN/A Pretax MarginN/A Return on Equity-31.62% Return on Assets-30.29% Debt Debt-to-Equity RatioN/A Current Ratio33.15 Quick Ratio33.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.60 per share Price / Book0.48Miscellaneous Outstanding Shares30,490,000Free Float21,098,000Market Cap$66.77 million OptionableOptionable Beta0.85 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:XBIT) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XBiotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
